Jazz Pharmaceuticals plc (JAZZ) stock
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30119% above fair value
$230.26−6.19 (-2.62%)
Close on Nov 20, 2026Market cap $14.95BP/E 75.0Yield –
Jazz Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Jazz Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2020 was $2.20B, up 9.5% year over year.
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | $611.15M | +12.9% |
| Q3 FY2020 | Sep 30, 2020 | $554.85M | +10.8% |
| Q2 FY2020 | Jun 30, 2020 | $530.20M | +6.9% |
| Q1 FY2020 | Mar 31, 2020 | $501.55M | +6.8% |
| Q4 FY2019 | Dec 31, 2019 | $541.18M | +22.7% |
| Q3 FY2019 | Sep 30, 2019 | $500.92M | +14.2% |
| Q2 FY2019 | Jun 30, 2019 | $495.75M | +7.4% |
| Q1 FY2019 | Mar 31, 2019 | $469.83M | +15.5% |
| Q4 FY2018 | Dec 31, 2018 | $441.00M | +8.9% |
| Q3 FY2018 | Sep 30, 2018 | $438.62M | +16.4% |
| Q2 FY2018 | Jun 30, 2018 | $461.38M | +27.8% |
| Q1 FY2018 | Mar 31, 2018 | $406.93M | +16.7% |
| Q4 FY2017 | Dec 31, 2017 | $404.85M | +12.8% |
| Q3 FY2017 | Sep 30, 2017 | $376.77M | – |
| Q2 FY2017 | Jun 30, 2017 | $360.98M | – |
| Q1 FY2017 | Mar 31, 2017 | $348.61M | – |
| Q4 FY2016 | Dec 31, 2016 | $358.96M | – |
See a number that looks wrong?